Kuei-Pin Chung1,2, Guan-Yuan Chen3,4, Tzu-Yi Chuang5,6, Yen-Tsung Huang7, Hou-Tai Chang8,9,10, Yen-Fu Chen1,11, Wei-Lun Liu12,13, Yi-Jung Chen6, Chia-Lin Hsu6, Miao-Tzu Huang14,15, Ching-Hua Kuo3,4,16, Chong-Jen Yu6,17. 1. Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. 2. Department of Laboratory Medicine, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan. 3. School of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan. 4. The Metabolomics Core Laboratory, Centers of Genomic Medicine and Precision Medicine, National Taiwan University, Taipei, Taiwan. 5. Department of Internal Medicine, Taoyuan General Hospital, Ministry of Health and Welfare, Taoyuan, Taiwan. 6. Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan. 7. Institute of Statistical Science, Academia Sinica, Taipei, Taiwan. 8. Department of Critical Care Medicine, Far Eastern Memorial Hospital, New Taipei, Taiwan. 9. Department of Industrial Engineering and Management, Yuan Ze University, Taoyuan, Taiwan. 10. Institute of Health Policy and Management, National Taiwan University, Taipei, Taiwan. 11. Department of Internal Medicine, National Taiwan University Hospital Yun-Lin Branch, Yun-Lin, Taiwan. 12. School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei, Taiwan. 13. Department of Emergency & Critical Care Medicine, Fu Jen Catholic University Hospital, New Taipei, Taiwan. 14. Department of Medical Research, National Taiwan University Hospital, Taipei, Taiwan. 15. Department of Pediatrics, National Taiwan University Hospital, Taipei, Taiwan. 16. Department of Pharmacy, National Taiwan University Hospital, Taipei, Taiwan. 17. Department of Internal Medicine, College of Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Abstract
OBJECTIVES: Recent metabolomic studies of sepsis showed that increased circulatory acylcarnitines were associated with worse survival. However, it is unknown whether plasma carnitine and acylcarnitines can reflect the severity of sepsis, and the role of specific acylcarnitines in prognostic assessment need further confirmation. This study aimed to clarify these questions. DESIGN: Prospective multicenter cohort studies with derivation and validation cohort design. SETTING: ICUs at two medical centers and three regional hospitals in Taiwan. PATIENTS: Patients with sepsis and acute organ dysfunction were enrolled. Recruitment of the derivation (n = 90) and validation cohorts (n = 120) occurred from October 2010 through March 2012 and January 2013 through November 2014, respectively. INTERVENTIONS: Plasma samples were collected immediately after admission, and the levels of carnitine and acylcarnitines were measured by ultra-high performance liquid chromatography-mass spectrometry. MEASUREMENTS AND MAIN RESULTS: In the derivation cohort, increased plasma levels of short- and medium-chain acylcarnitines were significantly associated with hepatobiliary dysfunction, renal dysfunction, thrombocytopenia, and hyperlactatemia. However, acetylcarnitine is the only acylcarnitine significantly correlating with various plasma cytokine concentrations and also associated with blood culture positivity and 28-day mortality risk. The association between plasma acetylcarnitine and multiple organ dysfunction severity, blood culture positivity, and 28-day mortality, was confirmed in the validation cohort. Patients with high plasma acetylcarnitine (≥ 6,000 ng/mL) had significantly increased 28-day mortality compared with those with plasma acetylcarnitine less than 6,000 ng/mL (52.6% vs 13.9%; hazard ratio, 5.293; 95% CI, 2.340-11.975; p < 0.001 by Cox proportional hazard model). CONCLUSIONS: We confirm that plasma acetylcarnitine can reflect the severity of organ dysfunction, inflammation, and infection in sepsis and can serve as a prognostic biomarker for mortality prediction.
OBJECTIVES: Recent metabolomic studies of sepsis showed that increased circulatory acylcarnitines were associated with worse survival. However, it is unknown whether plasma carnitine and acylcarnitines can reflect the severity of sepsis, and the role of specific acylcarnitines in prognostic assessment need further confirmation. This study aimed to clarify these questions. DESIGN: Prospective multicenter cohort studies with derivation and validation cohort design. SETTING: ICUs at two medical centers and three regional hospitals in Taiwan. PATIENTS: Patients with sepsis and acute organ dysfunction were enrolled. Recruitment of the derivation (n = 90) and validation cohorts (n = 120) occurred from October 2010 through March 2012 and January 2013 through November 2014, respectively. INTERVENTIONS: Plasma samples were collected immediately after admission, and the levels of carnitine and acylcarnitines were measured by ultra-high performance liquid chromatography-mass spectrometry. MEASUREMENTS AND MAIN RESULTS: In the derivation cohort, increased plasma levels of short- and medium-chain acylcarnitines were significantly associated with hepatobiliary dysfunction, renal dysfunction, thrombocytopenia, and hyperlactatemia. However, acetylcarnitine is the only acylcarnitine significantly correlating with various plasma cytokine concentrations and also associated with blood culture positivity and 28-day mortality risk. The association between plasma acetylcarnitine and multiple organ dysfunction severity, blood culture positivity, and 28-day mortality, was confirmed in the validation cohort. Patients with high plasma acetylcarnitine (≥ 6,000 ng/mL) had significantly increased 28-day mortality compared with those with plasma acetylcarnitine less than 6,000 ng/mL (52.6% vs 13.9%; hazard ratio, 5.293; 95% CI, 2.340-11.975; p < 0.001 by Cox proportional hazard model). CONCLUSIONS: We confirm that plasma acetylcarnitine can reflect the severity of organ dysfunction, inflammation, and infection in sepsis and can serve as a prognostic biomarker for mortality prediction.
Authors: Bryna L Fitzgerald; Claudia R Molins; M Nurul Islam; Barbara Graham; Petronella R Hove; Gary P Wormser; Linden Hu; Laura V Ashton; John T Belisle Journal: J Proteome Res Date: 2020-01-09 Impact factor: 4.466
Authors: Theodore S Jennaro; Michael A Puskarich; Marc R McCann; Christopher E Gillies; Manjunath P Pai; Alla Karnovsky; Charles R Evans; Alan E Jones; Kathleen A Stringer Journal: Pharmacotherapy Date: 2020-08-10 Impact factor: 4.705
Authors: Justin M Snider; Jeehyun Karen You; Xia Wang; Ashley J Snider; Brian Hallmark; Manja M Zec; Michael C Seeds; Susan Sergeant; Laurel Johnstone; Qiuming Wang; Ryan Sprissler; Tara F Carr; Karen Lutrick; Sairam Parthasarathy; Christian Bime; Hao Helen Zhang; Chiara Luberto; Richard R Kew; Yusuf A Hannun; Stefano Guerra; Charles E McCall; Guang Yao; Maurizio Del Poeta; Floyd H Chilton Journal: J Clin Invest Date: 2021-10-01 Impact factor: 14.808
Authors: Marc R McCann; Cora E McHugh; Maggie Kirby; Theodore S Jennaro; Alan E Jones; Kathleen A Stringer; Michael A Puskarich Journal: Metabolites Date: 2020-04-02